Clinuvel Pharmaceuticals Ltd has released a press release.
SCENESSE efficacy in vitiligo - new cases presented to EADV
Filed with ASX ·
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- Investor Presentation
- CLINUVEL delivers ninth consecutive revenues growth & profit
- Appendix 4E and Annual Report to Shareholders 2025
- CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist
- CLINUVEL preparing upgrade of ADR program, NASDAQ uplist
Later from Clinuvel Pharmaceuticals
- EMA approves year-round SCENESSE treatment
- CLINUVEL to advance novel pharmaceutical formulations in preclinical program
- CLINUVEL advances new formulations in preclinical program
- CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies
- CLINUVEL expands Singapore RD&I Centre
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals